PHILADELPHIA, PA; November 1, 2000 - Genmab A/S (CSE:GEN and Neuer Markt:GE9) announced today positive results from a Phase I/II clinical trial of HuMax™-CD4, a fully human antibody used to treat patients with rheumatoid arthritis. HuMax-CD4 was well tolerated in this dose escalating, placebo controlled study of 35 patients with severe rheumatoid arthritis, and there was no evidence of depletion of patients' CD4 positive T cells. Furthermore, in this single dose study, in the four highest dose cohorts, 0.5, 1, 2 and 4 mg/kg, fifty percent of the treated patients achieved favorable responses to the antibody, as measured by objective criteria that have been defined by the American College of Rheumatology and are routinely used by companies seeking regulatory approval of arthritis products. Eight of sixteen achieved ACR 20, one of those achieved ACR 50, and two of the group achieved ACR 70.

These data were presented today at the American College of Rheumatology Meeting in Philadelphia by Principal Investigator, Bo Baslund, M.D. of Rigshospitalet, Copenhagen.

"We are very encouraged by the HuMax-CD4 results," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "There are millions of people suffering from rheumatoid arthritis who are not responding to currently available therapies."

"This level of safety and activity in Phase I/II studies with severely diseased patients is unusually good," said Bo Baslund, M.D., Principal Investigator. "I look forward to the upcoming Phase II studies."

HuMax-CD4 is a fully human antibody that targets the CD4 receptor on T-cells. These cells are implicated early in the cascade of inflammatory events that cause rheumatoid arthritis. The scientific rationale for blocking the activity of these cells is to stop the inflammatory process.

Genmab A/S is a biotechnology company that creates and develops fully human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has four products in development to treat cancer, rheumatoid arthritis and other inflammatory conditions, and intends to assemble a broad portfolio of new therapeutic products arising from research into the human genome. At present, Genmab's commercial opportunities are based upon research conducted at leading international companies, such as Immunex, Oxford GlycoSciences, Eos Biotechnology and Medarex, as well as in its own laboratories. A broad alliance provides Genmab with access to Medarex's array of proprietary technologies, including the HuMab-Mouse®, for the rapid creation and development of fully human antibodies to virtually any disease target. For more information about Genmab, visit www.genmab.com.

Except for the historical information presented, certain matters discussed in this press release are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements such risks and uncertainties associated with product discovery and development including statements regarding the Company's clinical development programs and the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.

About HuMax™-CD4
HuMax™-CD4 is a high affinity fully human antibody created in the patented HuMab- Mouse system. Affinity measures the strength with which an antibody finds and adheres to its disease target. HuMax-CD4 has an unusually high affinity, 10 to the 11th power, noticeably higher in affinity than the best antibodies typically created in wild type mice. In addition to its unusual ability to attach to its target, because HuMax-CD4 is a fully human antibody it should not be recognized as a foreign protein by a patient's immune system and may be potent for a longer period of time than antibodies that are part mouse. It should also be less likely to cause immune reactions after repeated treatments. HuMax-CD4 targets the CD4 receptor on T-cells. These cells are implicated early in the cascade of inflammatory events that cause rheumatoid arthritis, psoriasis and other inflammatory diseases. The scientific rationale for blocking the activity of these cells is to stop the inflammatory process. Genmab believes that all these factors may be important in treating chronic inflammatory diseases like rheumatoid arthritis and psoriasis.